Início
Investigação Clínica
Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503

Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503

Dados básicos

Ensaios clínicos Nacional Finan. Não Competitivo Privada Ensaio Clínico Académico (INITIATE-HFrEF) 2022-502409-14-00 NCT05989503 Año de incio: 2023

Objectivos do projeto

Ensaio Clínico – Iniciativa do Investigador; Fase: IV – Aleatorizado; Subtipo: Tratamento – Medicamento (de baixo nivel de intervenção); Natureza do Promotor: Academia – Tipo não comercial; Tipo de Centro: Multicêntrico – 4 Centros de Cuidados Secundários – Centros de Ensaio: CHUSJ/CHVNGE/CHUdSA/Hospital Pedro Hispano; Doença investigada: Insuficiência cardíaca – Participantes recrutados: 20

Documentos

Não há documentos

Participantes

Francisco Aguiar Vasques Novoa Faria

Sub-Investigador
Joana Lídia Martins Pimenta

Sub-Investigador
Francisca Almeida Saraiva

Investigador Colaborador
João Pedro Melo Marques Pinho Ferreira

Investigador Principal
Ana Marta Matos Silva

Investigador Colaborador
Mário André Da Silva Santos

Sub-Investigador
Cristina Maria Rodrigues Pinheiro Gavina

Sub-Investigador

Unidades de investigação

Cirurgia e Fisiologia
Medicina
Medicina da Comunidade, Informação e Decisão em Saúde
RISE-Health

Investigador

Fernando Carlos De Landér Schmitt
Laboratório Associado RISE- Rede de Investigação em Saúde

Investigador

Fernando Carlos De Landér Schmitt

Stakeholders - Promotores

FMUP

Novartis

Outputs do ensaio clínico

Publicações em Livros 1
Publicações em Revistas 89
Teses 1

An Analysis From a Tertiary Pediatric Hospital: Does Physical Activity Play a Role in the Management of Children and Young Adults With Osteogenesis Imperfecta?

Saraiva, Francisca Galhardo; (...); Campagnolo, Joao Lameiras

Article. 10.7759/cureus.53646. 2024

Aortic stenosis rapid progression is associated with premature cardiac damage independently of baseline severity

Teixeira, R; (...); Fontes-Carvalho, R

Meeting Abstract. 2023

Author Correction: The European Reference Genome Atlas: piloting a decentralised approach to equitable biodiversity genomics.

Mc Cartney AM; (...); Mazzoni CJ

Correction. 10.1038/s44185-024-00065-3. 2024

Authors reply in response to a letter on "Standardized approach for extubation during extracorporeal membrane oxygenation in severe acute respiratory distress syndrome: a prospective observational study"

Roncon Albuquerque, R.; (...); Paiva, JA

Letter. 10.1186/s13613-023-01215-9. 2023

Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial

Sattar N.; (...); Anker S.D.

Article. 10.1002/ejhf.3221. 2024

Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme

Ferreira, JP; (...); Januzzi, JL

Article. 10.1002/ejhf.3166. 2024

Cardiovascular risk factors during pregnancy impact the postpartum cardiac and vascular reverse remodeling (vol 325, pg H774, 2023)

Ferreira, Ana Filipa; (...); Falcao-Pires, Ines

Correction. 10.1152/ajpheart.00200.2023_COR. 2024

Cardiovascular risk profile with SCORE2 and SCORE2-OP: comparing Portugal, Spain, Italy, and France using the new European predictive models

Fontainhas, Mariana; (...); Araujo, Francisco

Article. 10.3389/fcvm.2024.1509240. 2024

Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF

Shen L.; (...); McMurray J.J.V.

Article. 10.1161/CIRCULATIONAHA.124.070553. 2024

Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study.

Ferreira, JP; (...); Leite-Moreira, A

Article. 10.1016/j.atherosclerosis.2024.117461. 2024

Corrigendum: Reverse left ventricular remodeling after aortic valve replacement for aortic stenosis: a systematic review and meta-analysis(Front. Cardiovasc. Med., (2024), 11, (1407566), 10.3389/fcvm.2024.1407566)

Sousa Nunes F.; (...); Sousa C.

Correction. 10.3389/fcvm.2024.1471225. 2024

Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study.

Gavina, C; (...); Taveira Gomes, T

Article. 10.1002/clc.24183. 2024

Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF

Dewan P.; (...); McMurray J.J.V.

Article. 10.1161/CIRCULATIONAHA.124.068774. 2024

Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials

Ferreira, JP; (...); Zannad, F

Article. 10.1002/ejhf.3101. 2023

Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial

Wei, FF; (...); Staessen, JA

Article. 10.1038/s41440-024-01843-z. 2024

Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF

Dhingra, NK; (...); Packer, M

Article. 10.1016/j.jchf.2023.06.036. 2024

Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF.

Dhingra, NK; (...); Packer, M

Article. 2024

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved

Coats, AJS; (...); Anker, SD

Article. 10.1002/jcsm.13393. 2024

Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis

Ferreira, JP; (...); Anker, S

Article. 10.1002/ejhf.3180. 2024

Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes.

Ribeiro, E; (...); Vale, N

Article. 10.3390/jcm13144113. 2024

High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial.

Monzo, L; (...); Zannad, F

Article. 10.1016/j.cardfail.2023.11.020. 2024

High-Caloric Diets in Adolescence Impair Specific GABAergic Subpopulations, Neurogenesis, and Alter Astrocyte Morphology.

Mota, B; (...); Cardoso, A

Article. 10.3390/ijms25105524. 2024

High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT.

Ferreira, JP; (...); Solomon, SD

Article. 10.1016/j.ijcard.2024.131818. 2024

Home- versus centre-based EXercise InTervention in patients with Heart Failure (EXIT-HF trial): A pragmatic randomized controlled trial

Schmidt, C; (...); Santos, M

Article. 10.1016/j.repc.2023.05.013. 2024

Home- versus clinic-based exercise intervention in patients with heart failure (EXIT-HF trial): a pragmatic randomized controlled trial

Santos, M; (...); Ribeiro, F

Meeting Abstract. 2023

Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis

Talha, KM; (...); Packer, M

Article. 10.1111/dom.15572. 2024

Influence of iron deficiency definition on the efficacy of intravenous iron in heart failure: a meta-analysis of randomized trials

Marques P.; (...); Ferreira J.P.

Article. 10.1007/s00392-024-02557-5. 2024

Inhibition of circulating dipeptidyl-peptidase 3 by procizumab in experimental septic shock reduces catecholamine exposure and myocardial injury

Garcia, Bruno; (...); Herpain, Antoine

Article. 10.1186/s40635-024-00638-3. 2024

Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme

Ferreira J.P.; (...); Januzzi J.L.

Article. 10.1002/ejhf.3227. 2024

Is Reducing Heart Failure Hospitalization Associated With Reducing Mortality in Heart Failure Trials?

Marques P., Sharma A., Ferreira J.P.

Editorial Material. 10.1016/j.jchf.2024.01.011. 2024

Long-term cardiovascular outcomes in a population-based multicentric cohort of northern Portugal: Validation of the ESC/EAS prognostic risk classification.

Gavina, C; (...); Araújo, F

Article. 10.1016/j.jacl.2024.04.002. 2024

Lung ultrasound and diuretic therapy in chronic heart failure: a randomised trial.

Cruz, M; (...); Pimenta, J

Article. 10.1007/s00392-023-02238-9. 2024

MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials

Zannad F.; (...); Harrison S.A.

Review. 10.1111/joim.13793. 2024

Mineralocorticoid Receptor Antagonist Combined with SGLT2 Inhibitor versus SGLT2 Inhibitor Alone in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials

Ferreira J.P.; (...); Neves J.S.

Article. 10.1159/000541686. 2024

Office- versus home-based evaluation of quality of life in heart failure with reduced ejection fraction: A randomized study

de Almeida Pinho I.; (...); Ferreira J.P.

Article. 10.1016/j.ijcard.2024.132341. 2024

Pathophysiological Sex Differences in Heart Failure Progression AfterAcute Coronary Syndrome: Insights From the EXAMINE Trial

Razaghizad, A; (...); Sharma, A

Article. 10.1016/j.cardfail.2023.10.474. 2024

Pathophysiological Sex Differences in Heart Failure Progression AfterAcute Coronary Syndrome: Insights From the EXAMINE Trial.

Razaghizad, A; (...); Sharma, A

Article. 2024

Patiromer and MRA Doses in Patients With Current or Past Hyperkalemia

Ferreira J.P.

Editorial Material. 10.1016/j.jchf.2024.07.020. 2024

Perceptions of cardiology, professional preferences and impact on career choices among Portuguese cardiologists: Results from the Portuguese Society of Cardiology's Women and Cardiology Task Force survey.

Timóteo, AT; (...); Gonçalves, L

Article. 10.1016/j.repc.2023.07.004. 2024

Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort

Kobayashi M.; (...); Girerd N.

Article. 10.1002/ejhf.3202. 2024

Proteomics for understanding progression to heart failure in chronic kidney disease: promising but still not there

Zannad F., Ferreira J.P.

Editorial Material. 10.1093/eurheartj/ehae399. 2024

Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program

Packer M.; (...); Zannad F.

Article. 10.1016/j.jacc.2024.07.013. 2024

REGIONAL AND COUNTRY-SPECIFIC VARIATIONS IN CARDIOVASCULAR RISK PROFILES: A REAL-WORLD ANALYSIS

Araujo, Francisco; (...); Gavina, Cristina

Meeting Abstract. 2024

Reply to 'Empagliflozin and glucagon-like peptide-1 receptor agonists: The brothers for heart failure?'

Ferreira, JP, Voors, AA

Editorial Material. 10.1002/ejhf.3415. 2024

Reply to the letter entitled “Inflammation in Heart Failure with Preserved Ejection Fraction: A Bystander or A Participant?” by Zhong M and Yan X

Ferreira J.P., Zannad F., Solomon S.D.

Letter. 10.1016/j.ijcard.2024.132278. 2024

Reverse left ventricular remodeling after aortic valve replacement for aortic stenosis: a systematic review and meta-analysis

Sousa Nunes F.; (...); Sousa C.

Review. 10.3389/fcvm.2024.1407566. 2024

Risk of readmission and death after hospitalization for worsening heart failure: Role of post-discharge follow-up visits in a real-world study from the Grand Est Region of France

Baudry, G; (...); Girerd, N

Article. 10.1002/ejhf.3103. 2023

Standardized approach for extubation during extracorporeal membrane oxygenation in severe acute respiratory distress syndrome: a prospective observational study

Roncon Albuquerque, R.; (...); Paiva, J.

Article. 10.1186/s13613-023-01185-y. 2023

Stretch-induced compliance mechanism in pregnancy-induced cardiac hypertrophy and the impact of cardiovascular risk factors

Ferreira A.F.; (...); Falcão-Pires I.

Article. 10.1152/ajpheart.00701.2023. 2024

The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes A Meta-Analysis of Randomized Placebo-Controlled Trials

Mendonça, L; (...); Ferreira, JP

Article. 10.2215/CJN.0000000584. 2024

The win ratio in cardiology trials: lessons learnt, new developments, and wise future use

Pocock, SJ; (...); Stone, GW

Review. 10.1093/eurheartj/ehae647. 2024

Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE

Ferreira, JP; (...); Voors, AA

Article. 10.1002/ejhf.3369. 2024

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial

Tromp J.; (...); Voors A.A.

Article. 10.1002/ejhf.3218. 2024

Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial

Doehner W.; (...); Packer M.

Article. 10.1016/j.jchf.2024.08.020. 2024

Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

Yu, YL; (...); Staessen, JA

Article. 10.1136/heartjnl-2023-323796. 2024

Freedom And Smart Solo Stentless Bioprosthesis For Aortic Valve Replacement - Clinical And Hemodynamic Evaluation-Systematic Review And Meta-Analysis

Projeto de fim de curso

Colaboradores: Francisca Almeida Saraiva